SCHEMBL13309221

SCHEMBL13309221

Bc1cnn2c(Nc3ccc(S(=O)(=O)NCCO)cc3)cc(-c3ccccc3)nc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 3/20 0.44
▸ TP53 P04637 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ IKBKB O14920 2/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ HPGD P15428 1/20 0.43
▸ CLK1 P49759 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CA12 O43570 1/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA9 Q16790 1/20 0.42
▸ GSK3B P49841 4/20 0.42
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14528735 0.95 KDM4E (0.43) KDM4ETP53POLBIKBKBALDH1A1
SCHEMBL13309321 0.91 CDK2 (0.42) KDM4ETP53POLBIKBKBALDH1A1
SCHEMBL13308745 0.89 GSK3B (0.54) KDM4ETP53POLBIKBKBALDH1A1
SCHEMBL14528951 0.89 KDM4E (0.45) KDM4ETP53POLBALDH1A1MEN1
SCHEMBL13309059 0.89 IKBKB (0.44) KDM4ETP53POLBIKBKBALDH1A1
SCHEMBL14528805 0.86 KDM4E (0.46) KDM4ETP53POLBALDH1A1MEN1
SCHEMBL13309056 0.86 ATM (0.47) KDM4ETP53POLBALDH1A1KMT2A
SCHEMBL13309486 0.85 KDM4E (0.56) KDM4ETP53POLBALDH1A1MEN1
SCHEMBL13309050 0.85 ALDH1A1 (0.47) KDM4ETP53POLBALDH1A1MEN1
SCHEMBL13309084 0.85 KDM4E (0.40) KDM4ETP53POLBALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934224-B1 PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS FOR THE TREATMENT OF CANCER SCHERING CORP (US) 2010-06-09 — — EP disclosed
Send feedback